
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodie... Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23). Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.59 | -11.2413194444 | 23.04 | 23.3 | 19.86 | 523452 | 21.7140363 | CS |
4 | -0.32 | -1.54068367838 | 20.77 | 24.83 | 19.86 | 583246 | 22.4971 | CS |
12 | -7.13 | -25.852066715 | 27.58 | 29.06 | 19.86 | 546994 | 23.19028677 | CS |
26 | -5.42 | -20.9509083881 | 25.87 | 40.1 | 19.86 | 553355 | 27.10891558 | CS |
52 | -3.13 | -13.2739609839 | 23.58 | 47.97 | 19.86 | 557470 | 29.06055057 | CS |
156 | 9.64 | 89.1766882516 | 10.81 | 47.97 | 10.42 | 501129 | 28.39328193 | CS |
260 | 9.64 | 89.1766882516 | 10.81 | 47.97 | 10.42 | 501129 | 28.39328193 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions